Shop
eStoreRx™
Online Supplement Dispensary
Easy direct-to-patient ordering & fulfilment for Lifelong Wellness, eStoreRx™ is offered as part of the WholePractice membership or as a stand-alone program.
For over 40 years, Biotics Research Corporation has revolutionized the nutritional supplement industry by utilizing “The Best of Science and Nature”. Combining nature’s principles with scientific ingenuity, our products magnify the nutritional
This inclusive membership contains all of the the tools you need to grow your business, including WholeLifeRx™, Nimativ®, WholeLifeQ™, eStoreRx™ and Practice Success Programs.
Easy direct-to-patient ordering & fulfilment for Lifelong Wellness, eStoreRx™ is offered as part of the WholePractice membership or as a stand-alone program.
April 11 2024
A report on the intake of fish and omega-3 fatty acids among pregnant women in the U.S. was recently published in Public Health Nutrition. This analys...
A pilot study has provided evidence of the cost-saving benefits of the incorporation of serum-derived bovine immunoglobulin/protein isolate (SBI) into the therapeutic regimen of people with inflammatory bowel disease (IBD).
The lives of an estimated 1.8 million Americans are affected by IBD. With an annual direct cost of $6.4 billion in the US alone, it represents a medical and economic burden on patients, their families and the healthcare system. IBD is an umbrella term describing disorders that cause inflammation in the gastrointestinal tract, and the two most common forms are Crohn’s disease (CD) and ulcerative colitis (UC).
The primary goal of IBD therapies is clinical remission because this health problem is characterized by cycles of remission and relapse. Biologics currently being used for CD and UC include derivatives of antibodies such as anti-tumor necrosis factor alpha therapies, which work to dampen immune activation. Though biologic therapy is a common solution used to help with IBD, it is thought to be associated with significant costs.
This study charted retrospective data from 21 IBD patients receiving ongoing therapy at a gastrointestinal clinic. The researchers compared data from the patients’ medical records before as well as during 8 weeks of SBI administration. They also collected information from literature on the cost of SBI vs biologics.
The data analysis showed that 7 patients had secondary nonresponsiveness to biologics and the therapeutic regimens they were undergoing didn't result in adequate management of their IBD. When they were given 6 grams per day of SBI, the data showed better overall management and reduced the cost of biologic therapy by $1692 per patient.
The conclusion of this research was that significant yearly savings could be made by incorporating SBI into the diets of individuals with IBD as well as help effectively manage the condition.
Submit this form and you'll receive our latest news and updates.
Compelling research has shown positive outcomes for patients suffering from pouchitis using Serum-Derived Bovine Immunog...
Learn moreA retrospective case series review of people with Crohn’s disease (CD) and ulcerative colitis (UC) whose symptoms weren’...
Learn moreA case series of 10 patients with long-standing, symptomatic, intractable drug-refractory irritable bowel syndrome (IBS)...
Learn more
*These statements have not been evaluated by the Food and Drug Administration. This product has not intended to diagnose, treat, cure, or prevent any disease.
© 2023 Biotics Research Corporation - All Rights Reserved
Submit your comment